Botulinium Toxin-A, Children, Dysfunctional Voiding, Local Injection, Refractory Nocturnal Eneuresis
Conditions
Brief summary
The aim of this study is to evaluate the outcome of botulinum toxin A (BTX-A) injection for management of children with : A-Dysfunctional voiding who are not responding to traditional treatment. B-Refractory nocturnal enuresis.
Detailed description
Dysfunctional voiding (DV) is a habitual voiding disorder caused by involuntary contraction or non relaxation of the external urethral sphincter (EUS) during voiding. This contraction causes high post void residuals (PVR), The disorder can occur at any age. In young children it often presents as urinary incontinence, nocturnal enuresis, or recurrent urinary tract infections (UTIs). Nocturnal enuresis (NE) is common, affecting 15-20 % of children by five years old, and 8-10 % of children by eight years old. Refractory nocturnal enuresis is defined as monosymptomatic nocturnal enuresis (bedwetting without daytime urinary symptoms) that persists despite at least 3-6 months of appropriate and compliant first line therapy. Botulinum toxin has been found to inhibit the release of a number of neurotransmitters (including acetylcholine, adenosine triphosphate, and neuropeptides such as substance P) and to down regulate the expression of purinergic and capsaicin receptors on afferent neurons within the bladder.
Interventions
Patients will be injected with botulinium toxin-A
Sponsors
Study design
Eligibility
Inclusion criteria
* Children \< 18 years. * Both sexes. * Patients with refractory nocturnal enuresis or dysfunctional voiding who are not responding to the traditional treatment.
Exclusion criteria
* Bleeding disorders. * Neuromusclar disorder(e.g.,Myasthenia gravis). * Patients who are not fit for anaesthesia. * Active urinary tract infection (UTI).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Success rate | 24 hours postoperatively | Success rate regarding improvement of clinical symptoms will be recorded. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of complications | 24 hours postoperatively | Incidence of complications will be recorded. |
Countries
Egypt